Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier
about
Moving towards effective therapeutic strategies for Neuronal Ceroid LipofuscinosisNanostructures: a platform for brain repair and augmentationPeptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brainTargeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage DisordersEffective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brainLipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis.Identification and characterization of Nanobodies targeting the EphA4 receptor.Cancer research by means of tissue engineering--is there a rationale?Setting-up an in vitro model of rat blood-brain barrier (BBB): a focus on BBB impermeability and receptor-mediated transportLysosomal storage disease: gene therapy on both sides of the blood-brain barrier.Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.Toward reducing immunogenicity of enzyme replacement therapy: altering the specificity of human β-glucuronidase to compensate for α-iduronidase deficiency.Phage display as a tool to discover blood-brain barrier (BBB)-shuttle peptides: panning against a human BBB cellular model.Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease.Hematopoietic Stem cell transplantation and lentiviral vector-based gene therapy for Krabbe's disease: Present convictions and future prospects.Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome.Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma.Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery.Apolipoprotein E mimetic peptide protects against diffuse brain injury.Nanobodies as modulators of inflammation: potential applications for acute brain injury.Enzyme replacement in neuronal storage disorders in the pediatric population.RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy.Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.Bypassing the blood-brian barrier using established skull base reconstruction techniques.Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms.
P2860
Q26753109-77E78F8A-F78D-4B21-99EF-5F336BB0B63DQ27010023-FDCB181D-4323-4BB0-BF47-4B6D82121D5EQ27331875-E04A863D-EF7A-475D-B19B-85326D18F277Q28552459-55F1F7C4-5C2D-4EAF-8F37-8ABDA46959C7Q30573522-304F94DD-4F5C-4247-BE50-0FBC3988AA87Q30851435-20DBBC26-4447-4A61-A641-FE12D947E06BQ33882055-19D6EBB6-B231-44D3-A2CA-E3428EDD58CEQ34154747-B50B9FF1-3B1A-4482-9C87-7918AECF5DCAQ34400993-BE284E45-BE51-4085-A70D-326F5E635941Q35034401-D4F25944-4CA8-46C8-9EA1-A769EEB39ED4Q35600316-27797281-7827-448F-AFEE-387B7D2B5FAAQ35759492-AB811FEE-2F28-44E7-8BC2-55B729BA9D89Q36093633-111320AB-C6F7-4FE4-9119-AA7F30199D15Q36123828-8682CEEC-CEF2-404B-B757-E40016CA9501Q37265523-DDA201F9-4ECA-4FAE-99B3-DFBCC9C620EBQ37312010-27AB90E5-39C5-495D-AB8B-6E6DC54C8C93Q37599950-3AC49911-DF7C-4CA5-8A99-EEDE39ACAC57Q38265614-C97F2621-971D-456F-8DC8-EC6524CC138FQ38836486-B9DFA965-D0B5-42B7-84A9-1830C1B8E662Q41851758-6755BE9D-C3E0-49EA-8310-98A380B802E1Q42105969-CC8304E7-150F-42E4-956A-590B862EA52BQ43948150-6D6169B2-BD66-44C7-BAD9-FC0B9C3D18ABQ45875364-71F80923-2FED-4A60-A703-205762395247Q47373203-E174F78B-7ED1-4706-82B6-7089AEB061A5Q51746979-402C4397-7D6B-44FC-ACF9-71710206054AQ52147708-61D6DEA4-2B53-4643-9FDB-963F98E660C4Q55658045-76248894-4757-4BC7-BFBE-D0716228DF75
P2860
Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Engineering a lysosomal enzyme ...... across the blood-brain barrier
@ast
Engineering a lysosomal enzyme ...... across the blood-brain barrier
@en
type
label
Engineering a lysosomal enzyme ...... across the blood-brain barrier
@ast
Engineering a lysosomal enzyme ...... across the blood-brain barrier
@en
prefLabel
Engineering a lysosomal enzyme ...... across the blood-brain barrier
@ast
Engineering a lysosomal enzyme ...... across the blood-brain barrier
@en
P2093
P2860
P356
P1476
Engineering a lysosomal enzyme ...... across the blood-brain barrier
@en
P2093
Chia-Yi Kuan
Daren Wang
David Y Hui
Roscoe O Brady
Salim S El-Amouri
P2860
P304
P356
10.1073/PNAS.1222742110
P407
P577
2013-02-04T00:00:00Z